Intra-lesion injection of the recombinant form of EGF (rhEGF) directly at the site of the wound demonstrated a greater pharmacodynamic response in terms of granulation tissue growth and wound closure [44]; while PDGF-BB, FGFb, VEGF, and EGF were the most frequently used factors to improve the wound’s healing time, there were also clinical trials studying growth factors in the context of infection management. This evidence concerns the gene EGF and infection.